# Spravato: The Accessible Psychedelic Medicine with Amy Della Rocca, PMHNP

Page: https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/spravato-the-accessible-psychedelic-medicine-with-amy-della-rocca-pmhnp
Text version: https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/spravato-the-accessible-psychedelic-medicine-with-amy-della-rocca-pmhnp.md
Podcast: [Psychedelic Medicine Podcast with Dr. Lynn Marie Morski](https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820)
Published: 2026-04-09T09:00:00+00:00
Episode link: https://plantmedicinepodcast.libsyn.com/spravato-the-accessible-psychedelic-medicine-with-amy-della-rocca-pmhnp
Audio file: https://traffic.libsyn.com/secure/plantmedicinepodcast/Amy_Della_Rocca_FINAL.mp3?dest-id=1464755
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/episodes/spravato-the-accessible-psychedelic-medicine-with-amy-della-rocca-pmhnp
Duration seconds: 2576

## Resource

In this episode Amy Della Rocca, PMHNP joins to discuss Spravato, the FDA-approved prescription esketamine nasal spray, and its place in the field of psychedelic medicine. Amy is a psychiatric nurse practitioner and the Clinical Director of Marpa, a Spravato treatment center in New York. In this conversation, Amy offers a grounded and practical look at Spravato as one of the most accessible forms of psychedelic medicine currently available, especially for patients with treatment-resistant depression who may be priced out of intravenous or intramuscular ketamine treatments. She explains how insurance coverage, prior authorizations, and the 2025 shift allowing Spravato to be used as monotherapy have expanded access, while also walking through what treatment actually looks like in practice - from REMS monitoring and nasal spray administration to maintenance schedules and the importance of outside therapeutic support. Throughout, Amy emphasizes that Spravato can produce a wide spectrum of psychedelic effects, that it should not be dismissed as a "lesser" medicine because it is FDA-approved or pharmaceutical, and that the most effective treatment happens in a relational container that balances medical safety, emotional support, and realistic expectations about what the medicine can and cannot do. In this episode, you'll hear: What Spravato is and how it differs from other forms of ketamine treatment How insurance coverage, Medicaid, and copay assistance can make psychedelic care more financially accessible Which two diagnoses Spravato is approved to treat Why the 2025 approval of Spravato as a monotherapy meaningfully changed patient eligibility What a typical Spravato session looks like, including dosing, REMS monitoring, and maintenance treatment Why therapy, integration…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/episodes/spravato-the-accessible-psychedelic-medicine-with-amy-della-rocca-pmhnp/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/spravato-the-accessible-psychedelic-medicine-with-amy-della-rocca-pmhnp.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.